Breaking Finance News

Zacks Investment Research downgraded RPX Corp (NASDAQ:RPXC) to Hold in a report released today.

Only yesterday RPX Corp (NASDAQ:RPXC) traded -1.23% lower at $10.68. RPXC’s 50-day moving average is $10.50 and its 200-day moving average is $10.26. The last closing price is up 2.00% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. Trading volume was up over the average, with 322,426 shares of RPXC changing hands over the typical 262,362

Zacks Investment Research has downgraded RPX Corp (NASDAQ:RPXC) to Hold in a report released on 10/05/2016.

Previously on Thursday August 20, 2015, Barclays reported about RPX Corp (NASDAQ:RPXC) bumped up the target price from $0.00 to $15.00 that suggested a downside of -0.01%.

Recent Performance Chart

RPX Corp (NASDAQ:RPXC)

With a market capitalization of $0, RPX Corp has P/E ratio of 26.02 with a 52 week low of $8.60 and a 52 week high of $15.41 .

Brief Synopsis About RPX Corp (NASDAQ:RPXC)

RPX Corporation offers patent risk management solutions. The Company's patent risk management solution facilitates exchanges of value between owners and users of patents. The core of its solution is defensive patent aggregation, in which the Company acquires patents and licenses to patents that are being or may be asserted against its clients. The Company then licenses these patent assets to its clients to protect them from patent infringement assertions. The Company also provides its clients with access to its patent market intelligence and data. The Company acquires patent assets from various parties, including operating companies, individual inventors, non-practicing entities (NPEs), universities and bankruptcy trustees. Clients can access this market intelligence and data through its Web portal and through discussions with its client relations team. The Company also offers insurance to cover certain costs of patent litigation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *